Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jorge Castillo, M.D.

Title
Institution
Department
Address
Profile Picture

Biography
2012 - 2012
Best Lymphoma Abstract, Lymphoma & Myeloma 2012
1996 - 1996
Top 10%, UAM-X Medical School

Overview
Dr. Castillo was born in the northern coast of Peru. He received his medical degree in Mexico City, and completed his Hematology and Oncology training at Brown University. After 5 years as an Assistant Professor of Medicine at Brown University, Dr. Castillo was appointed Assistant Professor at Harvard Medical School. His clinical practice and research interests at the Dana-Farber Cancer Institute focus on patients with Waldenstrom Macroglobulinemia. He is currently the principal investigator in a series of clinical trials evaluating highly effective non-chemotherapeutic approaches.

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Cabrera ME, Peña C, Leon P, Lois V, Rojas H, Vega V, Pizarro A, Calderon S, Rojas C, Aspillaga A, Gonzalez ML, Intriago M, Rojas B, Hales C, Oliva J, Romero M, Capurro M, Castillo JJ. Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System. JCO Glob Oncol. 2022 Nov; 8:e2200165. PMID: 36351213.
    Citations:    Fields:    Translation:HumansPHPublic Health
  2. Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, Sevcikova S, Polackova P, Stork M, Knechtova Z, Venglar O, Kapustova V, Popkova T, Muronova L, Chyra Z, Hrdinka M, Simicek M, Garcés JJ, Puig N, Cedena MT, Jurczyszyn A, Castillo JJ, Penka M, Radocha J, Mateos MV, San-Miguel JF, Paiva B, Pour L, Rihova L, Hajek R. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma. J Clin Oncol. 2022 Oct 31; JCO2201226. PMID: 36315921.
    Citations:    Fields:    
  3. Muñoz J, Paludo J, Sarosiek S, Castillo JJ. Coming of Age for BTK Inhibitor Therapy: A Review of Zanubrutinib in Waldenström Macroglobulinemia. Cells. 2022 Oct 19; 11(20). PMID: 36291152; PMCID: PMC9600142.
    Citations:    Fields:    Translation:Humans
  4. Castillo J. EXABS-193-IBCL Using Biology to Determine Type and Duration of Treatment in Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 Suppl 2:S87-S88. PMID: 36164245.
    Citations:    Fields:    Translation:Humans
  5. Riva E, Duarte PJ, Valcárcel B, Remaggi G, Murrieta I, Corzo A, Del Carpio D, Peña C, Vásquez J, Bove V, Teixeira L, Fleury-Perini G, Yantorno S, Samánez C, Lopresti S, Altamirano M, Villela L, Ruiz-Arguelles GJ, Ruiz-Delgado GJ, Montaño E, Verri V, Zamora Pérez E, Pérez Jacobo F, Idrobo H, Martínez-Cordero H, Beltran BE, Ramírez J, Castillo JJ, Malpica Castillo LE. Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study. JCO Glob Oncol. 2022 08; 8:e2100380. PMID: 35939775; PMCID: PMC9470138.
    Citations:    Fields:    Translation:Humans
  6. Moreno DF, de Larrea CF, Castillo JJ. New treatment strategies for Waldenström macroglobulinemia. Clin Adv Hematol Oncol. 2022 Aug; 20(8):506-515. PMID: 36125957.
    Citations:    Fields:    Translation:HumansCells
  7. Durot E, Kanagaratnam L, Zanwar S, Toussaint E, Kastritis E, D'Sa S, Alcoceba M, Tomowiak C, Hivert B, Protin C, Abeykoon JP, Vos JMI, Michallet AS, Rodier C, Dupuis J, Leprêtre S, Merabet F, Roussel X, Zini JM, Regny C, Patel A, Morel P, Roos-Weil D, Treon SP, Dimopoulos MA, Garcia-Sanz R, Kapoor P, Castillo JJ, Delmer AJ. High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia. Blood Adv. 2022 06 28; 6(12):3655-3658. PMID: 35290439; PMCID: PMC9631579.
    Citations:    Fields:    Translation:Humans
  8. Munshi M, Liu X, Kofides A, Tsakmaklis N, Guerrera ML, Hunter ZR, Palomba ML, Argyropoulos KV, Patterson CJ, Canning AG, Meid K, Gustine J, Branagan AR, Flynn CA, Sarosiek S, Castillo JJ, Wang J, Buhrlage SJ, Gray NS, Munshi NC, Anderson KC, Treon SP, Yang G. A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Adv. 2022 06 14; 6(11):3332-3338. PMID: 35255496; PMCID: PMC9198919.
    Citations:    Fields:    Translation:Humans
  9. Castillo JJ, Sarosiek S, Flynn CA, Leventoff C, Little M, White T, Meid K, Treon SP. A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib. EJHaem. 2022 Aug; 3(3):927-929. PMID: 36051045; PMCID: PMC9421949.
    Citations:    
  10. Dittus C, Miller JA, Wehbie R, Castillo JJ. Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma. Br J Haematol. 2022 07; 198(2):e32-e34. PMID: 35506301.
    Citations: 1     Fields:    Translation:Humans
  11. Malpica L, Marques-Piubelli ML, Beltran BE, Chavez JC, Miranda RN, Castillo JJ. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022 07; 97(7):951-965. PMID: 35472248.
    Citations:    Fields:    Translation:HumansCells
  12. Gustine JN, Sarosiek S, Flynn CA, Meid K, Leventoff C, White T, Guerrera ML, Xu L, Kofides A, Tsakmaklis N, Munshi M, Demos M, Patterson CJ, Liu X, Yang G, Hunter ZR, Branagan AR, Treon SP, Castillo JJ. Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica. 2022 05 01; 107(5):1163-1171. PMID: 34162182; PMCID: PMC9052900.
    Citations:    Fields:    Translation:Humans
  13. Sarosiek S, Sermer D, Branagan AR, Treon SP, Castillo JJ. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Expert Rev Anticancer Ther. 2022 05; 22(5):471-478. PMID: 35404729.
    Citations:    Fields:    Translation:Humans
  14. Alderuccio JP, Arcaini L, Watkins MP, Beaven AW, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert AB, Olszewski AJ, Kim SH, Hess B, Gaballa S, Ayyappan S, Castillo JJ, Argnani L, Voorhees TJ, Saba R, Chowdhury SM, Vargas F, Reis IM, Kwon D, Alexander JS, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link BK, Logothetis CN, Herrera AF, Friedberg JW, Kahl BS, Luminari S, Zinzani PL, Lossos IS. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Adv. 2022 04 12; 6(7):2035-2044. PMID: 35196377; PMCID: PMC9006265.
    Citations: 1     Fields:    Translation:Humans
  15. Tahri S, Mouhieddine TH, Redd R, Lampe L, Nilsson KI, El-Khoury H, Su NK, Nassar AH, Adib E, Bindra G, Abou Alaiwi S, Trippa L, Steensma DP, Castillo JJ, Treon SP, Ghobrial IM, Sperling AS. Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. Blood Adv. 2022 04 12; 6(7):2230-2235. PMID: 34847227; PMCID: PMC9006277.
    Citations:    Fields:    Translation:Humans
  16. Derman B, Castillo JJ, Sarosiek S, Beksac M. When a Monoclonal Gammopathy Is Not Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-10. PMID: 35394823.
    Citations:    Fields:    Translation:Humans
  17. Sermer D, Sarosiek S, Branagan AR, Treon SP, Castillo JJ. SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2022 08; 22(8):547-556. PMID: 35339405.
    Citations:    Fields:    Translation:Humans
  18. Castillo JJ. A British view on the management of Waldenström macroglobulinemia. Br J Haematol. 2022 04; 197(2):133-134. PMID: 35138638.
    Citations:    Fields:    Translation:Humans
  19. Castillo JJ, Sarosiek SR, Gustine JN, Flynn CA, Leventoff CR, White TP, Meid K, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Hunter ZR, Patterson CJ, Branagan AR, Treon SP. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy. Blood Adv. 2022 02 08; 6(3):1015-1024. PMID: 34965304; PMCID: PMC8945307.
    Citations:    Fields:    Translation:Humans
  20. Mendoza R, Quiñones MP, Beltrán BE, Castro D, Paredes S, Miranda RN, Moisés C, Sánchez G, Castillo JJ, Torres-Cabala C. Primary cutaneous Epstein-Barr virus-positive B-cell lymphoid proliferation with features of diffuse large B-cell lymphoma and mucocutaneous ulcer: a diagnostic dilemma. Int J Dermatol. 2022 Jan 22. PMID: 35064673.
    Citations:    Fields:    
  21. Baljevic M, Sborov DW, Lim MY, Hillengass J, Martin T, Castillo JJ, Streiff MB, Kumar SK, Callander NS. Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma. J Natl Compr Canc Netw. 2022 01; 20(1):91-95. PMID: 34991076.
    Citations:    Fields:    Translation:Humans
  22. Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, Costello C, Devarakonda S, Elsedawy N, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Liedtke M, Martin T, Omel J, Sborov D, Shain K, Stockerl-Goldstein K, Weber D, Berardi RA, Kumar R, Kumar SK. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. J Natl Compr Canc Netw. 2022 01; 20(1):8-19. PMID: 34991075.
    Citations: 1     Fields:    Translation:Humans
  23. Cabrera ME, Marinov N, Roa M, Castillo JJ, Matutes E. Epidemiology of chronic lymphocytic leukemia in Chilean and Amerindian population in Chile. Leuk Lymphoma. 2022 05; 63(5):1137-1143. PMID: 34886754.
    Citations:    Fields:    Translation:Humans
  24. Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, White TP, Flynn CA, Sarosiek S, Branagan AR, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Patterson CJ, Hunter ZR, Davids MS, Furman RR, Treon SP. Venetoclax in Previously Treated Waldenström Macroglobulinemia. J Clin Oncol. 2022 01 01; 40(1):63-71. PMID: 34793256; PMCID: PMC8683218.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  25. Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos MG, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid K, Castillo JJ, Munshi NC, Anderson KC, Cameron M, Buhrlage SJ, Gray NS, Treon SP. The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021 11 18; 138(20):1966-1979. PMID: 34132782; PMCID: PMC8602936.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  26. Jalink M, Berentsen S, Castillo JJ, Treon SP, Cruijsen M, Fattizzo B, Cassin R, Fotiou D, Kastritis E, De Haas M, Oosten LEM, Frederiksen H, Patriarca A, D'Sa S, Vos JMI. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. Blood. 2021 11 18; 138(20):2002-2005. PMID: 34293088.
    Citations: 3     Fields:    Translation:Humans
  27. Durot E, Kanagaratnam L, Zanwar S, Kastritis E, D'Sa S, Garcia-Sanz R, Tomowiak C, Hivert B, Toussaint E, Protin C, Abeykoon JP, Guerrero-Garcia T, Itchaki G, Vos JM, Michallet AS, Godet S, Dupuis J, Leprêtre S, Bomsztyk J, Morel P, Leblond V, Treon SP, Dimopoulos MA, Kapoor P, Delmer A, Castillo JJ. A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica. 2021 11 01; 106(11):2940-2946. PMID: 33179472.
    Citations: 2     Fields:    Translation:Humans
  28. Jurczyszyn A, Castillo JJ, Olszewska-Szopa M, Kumar L, Thibaud S, Richter J, Flicker K, Fiala M, Vij R, Yi S, Xu F, Silbermann R, Gaisan CM, Ocio EM, Waszczuk-Gajda A, Crusoe EQ, Salomon-Perzynski A, Hus I, Valls JD, Gozzetti A, Czepiel J, Krzanowska K, Chappell A, Chellapuram SK, Suska A, Vesole DH. POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. Clin Lymphoma Myeloma Leuk. 2022 05; 22(5):297-304. PMID: 34844892.
    Citations:    Fields:    Translation:Humans
  29. Treon SP, Meid K, Hunter ZR, Flynn CA, Sarosiek SR, Leventoff CR, White TP, Cao Y, Roccaro AM, Sacco A, Demos MG, Guerrera ML, Kofides A, Liu X, Xu L, Patterson CJ, Munshi M, Tsakmaklis N, Yang G, Ghobrial IM, Branagan AR, Castillo JJ. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. Blood. 2021 10 28; 138(17):1535-1539. PMID: 34289017; PMCID: PMC8786275.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  30. Malpica L, Castro D, Enriquez DJ, Oviedo-Pecho R, Peña C, Idrobo H, Fiad L, Prates M, Valcarcel B, Paredes A, Sánchez G, Moisés C, Castillo JJ, Villela L, Ramos JC, Biglione M, Beltran BE. An international, multicenter, retrospective study on the positive impact of cutaneous involvement on the clinical outcome of adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2022 02; 63(2):315-325. PMID: 34585997.
    Citations:    Fields:    Translation:HumansCells
  31. Castillo JJ, Meid K, Gustine JN, Leventoff C, White T, Flynn CA, Sarosiek S, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Branagan AR, O'Donnell E, Raje N, Yee AJ, Patterson CJ, Hunter ZR, Treon SP. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 02; 36(2):532-539. PMID: 34531537; PMCID: PMC8807393.
    Citations: 4     Fields:    Translation:Humans
  32. Sarosiek S, Treon SP, Castillo JJ. How to Sequence Therapies in Waldenström Macroglobulinemia. Curr Treat Options Oncol. 2021 08 23; 22(10):92. PMID: 34426943.
    Citations: 2     Fields:    Translation:Humans
  33. Castillo JJ, LaMacchia J, Flynn CA, Sarosiek S, Pozdnyakova O, Treon SP. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. Br J Haematol. 2021 11; 195(3):466-468. PMID: 34355802.
    Citations:    Fields:    Translation:Humans
  34. Castillo JJ, Lamacchia J, Silver J, Flynn CA, Sarosiek S. Complete response to pembrolizumab and radiation in a patient with HIV-negative, EBV-positive plasmablastic lymphoma. Am J Hematol. 2021 10 01; 96(10):E390-E392. PMID: 34260089.
    Citations:    Fields:    Translation:HumansCells
  35. Kofides A, Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Munshi M, Liu X, Guerrera ML, Leventoff CR, White TP, Flynn CA, Meid K, Patterson CJ, Yang G, Branagan AR, Sarosiek S, Castillo JJ, Treon SP, Gustine JN. Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia. Hemasphere. 2021 Aug; 5(8):e624. PMID: 34291197; PMCID: PMC8288895.
    Citations: 3     
  36. Malpica L, Enriquez DJ, Castro DA, Peña C, Idrobo H, Fiad L, Prates M, Otero V, Biglione M, Altamirano M, Sandival-Ampuero G, Aviles-Perez U, Meza K, Aguirre-Martinez L, Cristaldo N, Maradei JL, Guanchiale L, Soto P, Viñuela JL, Cabrera ME, Paredes SR, Riva E, Di Stefano M, Noboa A, Choque JA, Candelaria M, Von Glasenapp A, Valvert F, Torres-Viera MA, Castillo JJ, Ramos JC, Villela L, Beltran BE. Real-World Data on Adult T-Cell Leukemia/Lymphoma in Latin America: A Study From the Grupo de Estudio Latinoamericano de Linfoproliferativos. JCO Glob Oncol. 2021 07; 7:1151-1166. PMID: 34270330.
    Citations: 1     Fields:    Translation:Humans
  37. Castillo JJ, Beltran BE, Malpica L, Marques-Piubelli ML, Miranda RN. Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK?+?LBCL): a systematic review of clinicopathological features and management. Leuk Lymphoma. 2021 12; 62(12):2845-2853. PMID: 34151703.
    Citations:    Fields:    Translation:Humans
  38. Martz CA, Jarbeau JF, Castillo JJ, Fisher DC, Nohria A. Medical Management of Hemodynamically Unstable Sinoatrial Node Dysfunction in a Patient With Intracardiac Lymphoma. JACC CardioOncol. 2021 Jun; 3(2):326-329. PMID: 34396343.
    Citations:    
  39. Mozessohn L, Zhang L, Odejide OO, Chen R, Buckstein R, Soiffer RJ, Castillo JJ, Driver JA, Abel GA. Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leuk Lymphoma. 2021 12; 62(12):2882-2889. PMID: 34114930.
    Citations:    Fields:    Translation:Humans
  40. Demos MG, Hunter ZR, Xu L, Tsakmaklis N, Kofides A, Munshi M, Liu X, Guerrera ML, Leventoff CR, White TP, Flynn CA, Meid K, Patterson CJ, Yang G, Branagan AR, Sarosiek S, Castillo JJ, Treon SP, Gustine JN. Cell-free DNA analysis for detection of MYD88L265P and CXCR4S338X mutations in Waldenström macroglobulinemia. Am J Hematol. 2021 07 01; 96(7):E250-E253. PMID: 33819355.
    Citations: 3     Fields:    Translation:Humans
  41. Castillo JJ, Callander NS, Baljevic M, Sborov DW, Kumar S. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol. 2021 07 01; 96(7):846-853. PMID: 33709474.
    Citations: 1     Fields:    Translation:HumansAnimals
  42. Gustine JN, Xu L, Yang G, Liu X, Kofides A, Tsakmaklis N, Munshi M, Demos M, Guerrera ML, Meid K, Patterson CJ, Sarosiek S, Branagan AR, Hunter ZR, Castillo JJ, Treon SP. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia. Br J Haematol. 2021 08; 194(4):730-733. PMID: 33713429; PMCID: PMC9113056.
    Citations: 4     Fields:    Translation:Humans
  43. Sarosiek S, Treon SP, Castillo JJ. Reducing treatment toxicity in Waldenström macroglobulinemia. Expert Opin Drug Saf. 2021 Jun; 20(6):669-676. PMID: 33645373.
    Citations:    Fields:    Translation:Humans
  44. Branagan AR, Lei M, Treon SP, Castillo JJ. Clinical application of genomics in Waldenström macroglobulinemia. Leuk Lymphoma. 2021 08; 62(8):1805-1815. PMID: 33569985.
    Citations:    Fields:    Translation:Humans
  45. Castro D, Beltrán B, Quiñones MDP, Pachas C, Huerta Y, Lalupu K, Mendoza R, Castillo JJ. Clinical, inflammatory and immunohistochemical features in a cohort of Peruvian patients with diffuse large B-cell lymphoma. Leuk Res. 2021 03; 102:106513. PMID: 33561632.
    Citations: 1     Fields:    Translation:Humans
  46. Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S, D'Sa S, Owen RG, Cull G, Mulligan S, Czyz J, Castillo JJ, Motta M, Siddiqi T, Gironella Mesa M, Granell Gorrochategui M, Talaulikar D, Zinzani PL, Askari E, Grosicki S, Oriol A, Rule S, Kloczko J, Tedeschi A, Buske C, Leblond V, Trotman J, Chan WY, Michel J, Schneider J, Tan Z, Cohen A, Huang J, Tam CS. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020 12 08; 4(23):6009-6018. PMID: 33284944; PMCID: PMC7724905.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  47. Castillo JJ, Treon SP. Management of Waldenström macroglobulinemia in 2020. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):372-379. PMID: 33275726.
    Citations: 6     Fields:    Translation:Humans
  48. Kumar SK, Callander NS, Adekola K, Anderson L, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Kang Y, Hultcrantz M, Larson S, Liedtke M, Martin T, Omel J, Shain K, Sborov D, Stockerl-Goldstein K, Weber D, Keller J, Kumar R. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 12 02; 18(12):1685-1717. PMID: 33285522.
    Citations: 30     Fields:    Translation:HumansCells
  49. Castillo JJ, Abeykoon JP, Gustine JN, Zanwar S, Mein K, Flynn CA, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, King R, Yang G, Hunter ZR, Advani RH, Palomba ML, Ansell SM, Gertz MA, Kapoor P, Treon SP. Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. Br J Haematol. 2021 02; 192(3):542-550. PMID: 33207010; PMCID: PMC8937605.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  50. Castillo JJ, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Talaulikar D, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020 Nov; 7(11):e827-e837. PMID: 33091356.
    Citations: 24     Fields:    Translation:Humans
  51. Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020 10 29; 136(18):2038-2050. PMID: 32731259; PMCID: PMC7596850.
    Citations: 63     Fields:    Translation:HumansCTClinical Trials
  52. Castillo JJ, Libby EN, Ansell SM, Palomba ML, Meid K, Flynn CA, Leventoff C, Hergott CB, Sewastianik T, Morgan EA, Carrasco R, Fromm JR, Yang G, Hunter Z, Treon SP. Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. Blood Adv. 2020 10 27; 4(20):5089-5092. PMID: 33085756.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  53. Jiménez C, Xu L, Tsakmaklis N, Demos MG, Kofides A, Chan GG, Guerrera ML, Chen JG, Liu X, Munshi M, Patterson CJ, Yang G, Castillo JJ, Treon SP, Hunter ZR. Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia. Blood Adv. 2020 09 22; 4(18):4550-4553. PMID: 32956451.
    Citations: 2     Fields:    Translation:Humans
  54. Treon SP, Meid K, Gustine J, Yang G, Xu L, Liu X, Patterson CJ, Hunter ZR, Branagan AR, Laubach JP, Ghobrial IM, Palomba ML, Advani R, Castillo JJ. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2021 02 20; 39(6):565-575. PMID: 32931398; PMCID: PMC8078354.
    Citations: 29     Fields:    Translation:Humans
  55. Castillo JJ, Meid K, Flynn CA, Chen J, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Yang G, Hunter Z, Treon SP. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. Blood Adv. 2020 08 25; 4(16):3952-3959. PMID: 32822482; PMCID: PMC7448596.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  56. Talaulikar D, Advani RH, Branagan AR, Buske C, Dimopoulos MA, D'Sa S, Kersten MJ, Leblond V, Minnema MC, Owen RG, Palomba ML, Tedeschi A, Trotman J, Varettoni M, Vos JM, Treon SP, Kastritis E, Castillo JJ. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. Hemasphere. 2020 Aug; 4(4):e433. PMID: 32803133.
    Citations: 2     
  57. Suska A, Vesole DH, Castillo JJ, Kumar SK, Parameswaran H, Mateos MV, Facon T, Gozzetti A, Mikala G, Szostek M, Mikhael J, Hajek R, Terpos E, Jurczyszyn A. Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers? Clin Hematol Int. 2020 Dec; 2(4):133-142. PMID: 34595454.
    Citations: 1     
  58. Jurczyszyn A, Waszczuk-Gajda A, Castillo JJ, Krawczyk K, Stork M, Pour L, Usnarska-Zubkiewicz L, Potoczek S, Hus I, Davila Valls J, Hari P, Chhabra S, Gentile M, Mikala G, Varga G, Chim CS, Fiala M, Vij R, Schutz N, Rodzaj M, Porowska A, Vesole DH, Druzd-Sitek A, Walewski J, Nooka AK. Primary refractory multiple myeloma: a real-world experience with 85 cases. Leuk Lymphoma. 2020 12; 61(12):2868-2875. PMID: 32623944.
    Citations: 1     Fields:    Translation:Humans
  59. Aguilar C, Laberiano C, Beltran B, Diaz C, Taype-Rondan A, Castillo JJ. Clinicopathologic characteristics and survival of patients with primary effusion lymphoma. Leuk Lymphoma. 2020 09; 61(9):2093-2102. PMID: 32449626.
    Citations: 4     Fields:    Translation:HumansCells
  60. Castillo JJ, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. Hemasphere. 2020 Jun; 4(3):e363. PMID: 32647793.
    Citations: 3     
  61. Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, Meid K, Yang G. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915. PMID: 32302379; PMCID: PMC7243149.
    Citations: 131     Fields:    Translation:HumansCellsPHPublic Health
  62. Beltrán BE, Villela L, Torres MA, Otero V, Fiad L, Peña C, Cabrera ME, León P, Idrobo H, Castro DA, Paredes S, Perdomo I, Abello V, Rojas C, Ramirez-Ibargüen A, Candelaria M, Pérez-Jacobo F, Montaño-Figueroa E, Best C, Goméz-De Leon A, Gómez-Almaguer D, Ruiz-Argüelles G, Hernández-Hernández J, Malpica L, Sotomayor EM, Castillo JJ. A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin